Skip to main content

Analytical performance and clinical concordance of the cancer biomarkers CA 15-3, CA 19-9, CA 125 II, Carcinoembryonic Antigen, and Alpha-Fetoprotein on the Dimension Vista® System.

Christenson RH, Cervelli DR, Sterner J, Bachmann LM, Rebuck H, Gray J, Kelley WE

Publication: Clin Biochem (2011) • Vol 44 • Page 1128-36PMID: 21704611View on PubMed

Purpose

The purpose of this paper was to evaluate the effects of anticoagulant, storage, and assay type on the measurement of cancer biomarkers.

Conclusion

The type of anticoagulant used had no effect on the measurement of CA 15-3, CA19-9, CA 125 II, AFP or CEA. Most markers decreased slightly after storage at all temperatures, regardless of anticoagulant. There was a high degree of correlation between measurements taken on each of the different autoanalyzers over the course of treatments.

Studies (1)

Purpose

The purpose of this study was to evaluate the effects of anticoagulant, storage, and assay type on the measurement of cancer biomarkers in blood.

Summary of Findings

For the Dimension VISTA assay, the type of anticoagulant used had no effects on the measurement of CA 15-3, CA19-9, CA 125 II, AFP or CEA. After storage for 12 months at -70 degrees C or -20 degrees C, more than 90% of CA 15-3 and CA 19-9 was recovered from serum, lithium heparin-plasma, sodium heparin-plasma and 4 of 5 EDTA specimens, the fifth one having 81% of CA 19-9 recovered. After storage for 9 months at -70 degrees C, more than 90% of CA 125 II was recovered from serum and plasma, regardless of anticoagulant; however, after 9 months of storage at -20 degrees C, only 89% of CA 125 was recovered from lithium heparin specimens, but more than 90% of CA 125 was recovered with all other anticoagulants. After storage of serum or lithium heparin specimens for 7 days at 4 degrees C or 7 or 120 days at -20 degrees C, more than 93.7% of AFP was recovered. CEA recovery was greater than 96.7% for specimens stored for 7 days at any temperature and greater than 98.6% for specimens stored at -20 or -70 degrees C. CEA was lower in non-smokers than in smokers. A high degree of correlation was found between the Dimension VISTA and other analyzers during the course of patient treatment. Overall expression level patterns agreed for CA 15-3, CA 19-9, CA 125 II, AFP and CEA in 89% of breast cancer, 92% of pancreatic cancer, 98% ovarian cancer, 90% of testicular cancer and 94% of colorectal cancer specimens, respectively. Lot to lot correlation between reagents on the Dimension Vista was high.

  • Biospecimens

    FluidBlood
    FluidPlasma
    FluidSerum
  • Preservation Types

    None (Fresh)Frozen
  • Diagnoses

    NeoplasticCarcinoma
    Neoplastic
  • Platforms

    ProteinClinical chemistry/auto analyzer
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    Biospecimen AcquisitionAnticoagulant
    EDTA
    Lithium heparin
    None
    Sodium heparin
    Biospecimen PreservationType of fixation/preservation
    Frozen
    None (fresh)
    StorageStorage duration
    0 days
    12 months
    120 days
    7 days
    9 months
    StorageStorage temperature
    -20 degrees C
    -70 degrees C
    4 degrees C
    Clinical chemistry/auto analyzer SpecificDetection method
    Lot 1
    Lot 2
    Clinical chemistry/auto analyzer SpecificTechnology platform
    ADVIA Centaur
    Abbott AxSym
    Beckmann Access
    Dimension VISTA